An L2 SUMO interacting motif is important for PML localization and infection of human papillomavirus type 16

Cellular Microbiology

Volumn 16, Issue 8, 2014, Pages 1179-1200

  Bund, Timo ^a,b   Spoden, Gilles A ^b   Koynov, Kaloian ^a   Hellmann, Nadja ^c   Boukhallouk, Fatima ^b   Arnold, Philipp ^c   Hinderberger, Dariush ^a,d   Florin, Luise ^b  

^a MAX PLANCK INSTITUTE FOR POLYMER RESEARCH   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

L1 PROTEIN; L2 PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; SUMO PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; CAPSID PROTEIN; L2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; NUCLEAR PROTEIN; ONCOPROTEIN; PML PROTEIN, HUMAN; SUMO 1 PROTEIN; SUMO2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; VIRUS ANTIGEN; ZINC FINGER PROTEIN;

ARTICLE; CELL NUCLEUS INCLUSION BODY; DNA VIRUS; GENE OVEREXPRESSION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOPRECIPITATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; SUMOYLATION; VIRUS CAPSID; VIRUS INFECTION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HUMAN; METABOLISM; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MIRIDAE; PAPILLOMAVIRIDAE;

ANTIGENS, VIRAL; CAPSID PROTEINS; CELL LINE, TUMOR; HEK293 CELLS; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MOLECULAR DYNAMICS SIMULATION; NUCLEAR PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PROTEIN STRUCTURE, TERTIARY; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMO-1 PROTEIN; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; ZINC FINGERS;

EID: 84904986129     PISSN: 14625814     EISSN: 14625822     Source Type: Journal    
DOI: 10.1111/cmi.12271     Document Type: Article

References (98)

1. Baker, T.S., Newcomb, W.W., Olson, N.H., Cowsert, L.M., Olson, C., and Brown, J.C. (1991) Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J 60: 1445-1456.
2. Becker, K.A., Florin, L., Sapp, C., and Sapp, M. (2003) Dissection of human papillomavirus type 33L2 domains involved in nuclear domains (ND) 10 homing and reorganization. Virology 314: 161-167.
3. Becker, K.A., Florin, L., Sapp, C., Maul, G.G., and Sapp, M. (2004) Nuclear localization but not PML protein is required for incorporation of the papillomavirus minor capsid protein L2 into virus-like particles. J Virol 78: 1121-1128.
4. Bienkowska-Haba, M., Patel, H.D., and Sapp, M. (2009a) Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog 5: e1000524.
5. Bienkowska-Haba, M., Patel, H.D., and Sapp, M. (2009b) Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog 5: e1000524.
6. Bienkowska-Haba, M., Williams, C., Kim, S.M., Garcea, R.L., and Sapp, M. (2012) Cyclophilins facilitate dissociation of the HPV16 capsid protein L1 from the L2/DNA complex following virus entry. J Virol 86: 9875-9887.
7. Boddy, M.N., Howe, K., Etkin, L.D., Solomon, E., and Freemont, P.S. (1996) PIC1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13: 971-982.
8. Boutell, C., Cuchet-Lourenco, D., Vanni, E., Orr, A., Glass, M., McFarlane, S., and Everett, R.D. (2011) A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog 7: e1002245.
9. Buck, C.B., and Trus, B.L. (2012) The papillomavirus virion: a machine built to hide molecular Achilles' heels. Adv Exp Med Biol 726: 403-422.
10. Buck, C.B., Pastrana, D.V., Lowy, D.R., and Schiller, J.T. (2004) Efficient intracellular assembly of papillomaviral vectors. J Virol 78: 751-757.
11. Buck, C.B., Cheng, N., Thompson, C.D., Lowy, D.R., Steven, A.C., Schiller, J.T., and Trus, B.L. (2008) Arrangement of L2 within the papillomavirus capsid. J Virol 82: 5190-5197.
12. Cerqueira, C., and Schelhaas, M. (2012) Principles of polyoma- and papillomavirus uncoating. Med Microbiol Immunol 201: 427-436.
13. Cerqueira, C., Liu, Y., Kuhling, L., Chai, W., Hafezi, W., van Kuppevelt, T.H., etal. (2013) Heparin increases the infectivity of Human Papillomavirus Type 16 independent of cell surface proteoglycans and induces L1 epitope exposure. Cell Microbiol 15: 1818-1836.
14. Chiang, C.M., Ustav, M., Stenlund, A., Ho, T.F., Broker, T.R., and Chow, L.T. (1992) Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proc Natl Acad Sci USA 89: 5799-5803.
15. Darshan, M.S., Lucchi, J., Harding, E., and Moroianu, J. (2004) The L2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptors. J Virol 78: 12179-12188.
16. Dasgupta, J., Bienkowska-Haba, M., Ortega, M.E., Patel, H.D., Bodevin, S., Spillmann, D., etal. (2011) Structural basis of oligosaccharide receptor recognition by human papillomavirus. J Biol Chem 286: 2617-2624.
17. Day, P.M., Roden, R.B., Lowy, D.R., and Schiller, J.T. (1998) The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J Virol 72: 142-150.
18. Day, P.M., Baker, C.C., Lowy, D.R., and Schiller, J.T. (2004) Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci USA 101: 14252-14257.
19. Day, P.M., Thompson, C.D., Schowalter, R.M., Lowy, D.R., and Schiller, J.T. (2013) Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection. J Virol 87: 3862-3870.
20. Doorbar, J. (2005) The papillomavirus life cycle. J Clin Virol 32 (Suppl. 1): S7-S15.
21. Evander, M., Frazer, I.H., Payne, E., Qi, Y.M., Hengst, K., and McMillan, N.A. (1997) Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 71: 2449-2456.
22. Everett, R.D. (2001) DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 29: 7266-7273.
23. Everett, R.D., and Chelbi-Alix, M.K. (2007) PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89: 819-830.
24. Florin, L., Sapp, C., Streeck, R.E., and Sapp, M. (2002a) Assembly and translocation of papillomavirus capsid proteins. J Virol 76: 10009-10014.
25. Florin, L., Schafer, F., Sotlar, K., Streeck, R.E., and Sapp, M. (2002b) Reorganization of nuclear domain 10 induced by papillomavirus capsid protein l2. Virology 295: 97-107.
26. Florin, L., Becker, K.A., Lambert, C., Nowak, T., Sapp, C., Strand, D., etal. (2006) Identification of a dynein interacting domain in the papillomavirus minor capsid protein L2. J Virol 80: 6691-6696.
27. Florin, L., Sapp, M., and Spoden, G.A. (2012) Host-cell factors involved in papillomavirus entry. Med Microbiol Immunol 201: 437-448.
28. Gareau, J.R., and Lima, C.D. (2010) The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 11: 861-871.
29. Giroglou, T., Florin, L., Schäfer, F., Streeck, R.E., and Sapp, M. (2001) Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75: 1565-1570.
30. Gonzalez-Santamaria, J., Campagna, M., Garcia, M.A., Marcos-Villar, L., Gonzalez, D., Gallego, P., etal. (2011) Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins. J Virol 85: 12890-12900.
31. Goujon, M., McWilliam, H., Li, W., Valentin, F., Squizzato, S., Paern, J., and Lopez, R. (2010) A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic Acids Res 38 (Suppl.): W695-W699.
32. Graham, S.V. (2008) Papillomavirus 3' UTR regulatory elements. Front Biosci 13: 5646-5663.
33. Guo, D., Li, M., Zhang, Y., Yang, P., Eckenrode, S., Hopkins, D., etal. (2004) A functional variant of SUMO4, a new IκBα modifier, is associated with type 1 diabetes. Nat Genet 36: 837-841.
34. Hannich, J.T., Lewis, A., Kroetz, M.B., Li, S.J., Heide, H., Emili, A., and Hochstrasser, M. (2005) Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J Biol Chem 280: 4102-4110.
35. Howley, P.M., Knipe, D.M., and Fields, B.N. (2007) Fields Virology. Philadelphia, PA: Lippincott Williams & Wilkins.
36. Isas, J.M., Langen, R., Haigler, H.T., and Hubbell, W.L. (2002) Structure and dynamics of a helical hairpin and loop region in annexin 12: a site-directed spin labeling study. Biochemistry 41: 1464-1473.
37. Ishii, Y., Tanaka, K., Kondo, K., Takeuchi, T., Mori, S., and Kanda, T. (2010) Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody. Virology 406: 181-188.
38. Johnson, E.S. (2004) Protein modification by SUMO. Annu Rev Biochem 73: 355-382.
39. Joyce, J., Tung, J., Przysiecki, C., Cook, J., Lehman, E., Sands, J., etal. (1999) The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274: 5810-5822.
40. Kamitani, T., Kito, K., Nguyen, H.P., Fukuda-Kamitani, T., and Yeh, E.T. (1998) Characterization of a second member of the sentrin family of ubiquitin-like proteins. J Biol Chem 273: 11349-11353.
41. Kawana, K., Matsumoto, K., Yoshikawa, H., Taketani, Y., Kawana, T., Yoshiike, K., and Kanda, T. (1998) A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. Virology 245: 353-359.
42. Kämper, N., Day, P.M., Nowak, T., Selinka, H.C., Florin, L., Bolscher, J., etal. (2006) A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol 80: 759-768.
43. Kerscher, O., Felberbaum, R., and Hochstrasser, M. (2007) SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep 8: 550-555.
44. Kim, E.T., Kim, Y.E., Huh, Y.H., and Ahn, J.H. (2010) Role of noncovalent SUMO binding by the human cytomegalovirus IE2 transactivator in lytic growth. J Virol 84: 8111-8123.
45. Laimins, L.A. (1993) The biology of human papillomaviruses: from warts to cancer. Infect Agents Dis 2: 74-86.
46. Larkin, M.A., Blackshields, G., Brown, N.P., Chenna, R., McGettigan, P.A., McWilliam, H., etal. (2007) ClustalW and ClustalX version 2. Bioinformatics 23: 2947-2948.
47. Leder, C., Kleinschmidt, J.A., Wiethe, C., and Muller, M. (2001) Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol 75: 9201-9209.
48. Lipovsky, A., Popa, A., Pimienta, G., Wyler, M., Bhan, A., Kuruvilla, L., etal. (2013) Genome-wide siRNA screen identifies the retromer as a cellular entry factor for human papillomavirus. Proc Natl Acad Sci USA 110: 7452-7457.
49. Loftus, L.T., Gala, R., Yang, T., Jessick, V.J., Ashley, M.D., Ordonez, A.N., etal. (2009) Sumo-2/3-ylation following in vitro modeled ischemia is reduced in delayed ischemic tolerance. Brain Res 1272: 71-80.
50. Mchaourab, H.S., Lietzow, M.A., Hideg, K., and Hubbell, W.L. (1996) Motion of spin-labeled side chains in T4 lysozyme. Correlation with protein structure and dynamics. Biochemistry 35: 7692-7704.
51. Mamoor, S., Onder, Z., Karanam, B., Kwak, K., Bordeaux, J., Crosby, L., etal. (2012) The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic. Virology 422: 413-424.
52. Marusic, M.B., Mencin, N., Licen, M., Banks, L., and Grm, H.S. (2010) Modification of human papillomavirus minor capsid protein L2 by sumoylation. J Virol 84: 11585-11589.
53. Matunis, M.J., Coutavas, E., and Blobel, G. (1996) A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol 135: 1457-1470.
54. Meulmeester, E., Kunze, M., Hsiao, H.H., Urlaub, H., and Melchior, F. (2008) Mechanism and consequences for paralog-specific sumoylation of ubiquitin-specific protease 25. Mol Cell 30: 610-619.
55. Mikolajczyk, J., Drag, M., Bekes, M., Cao, J.T., Ronai, Z., and Salvesen, G.S. (2007) Small ubiquitin-related modifier (SUMO)-specific proteases: profiling the specificities and activities of human SENPs. J Biol Chem 282: 26217-26224.
56. Minty, A., Dumont, X., Kaghad, M., and Caput, D. (2000) Covalent modification of p73α by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 275: 36316-36323.
57. Modis, Y., Trus, B.L., and Harrison, S.C. (2002) Atomic model of the papillomavirus capsid. EMBO J 21: 4754-4762.
58. Munger, K., Hayakawa, H., Nguyen, C.L., Melquiot, N.V., Duensing, A., and Duensing, S. (2006) Viral carcinogenesis and genomic instability. EXS 96: 179-199.
59. Okura, T., Gong, L., Kamitani, T., Wada, T., Okura, I., Wei, C.F., etal. (1996) Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J Immunol 157: 4277-4281.
60. Ouyang, J., Shi, Y., Valin, A., Xuan, Y., and Gill, G. (2009) Direct binding of CoREST1 to SUMO-2/3 contributes to gene-specific repression by the LSD1/CoREST1/HDAC complex. Mol Cell 34: 45-154.
61. Owerbach, D., McKay, E.M., Yeh, E.T., Gabbay, K.H., and Bohren, K.M. (2005) A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun 337: 517-520.
62. Raff, A.B., Woodham, A.W., Raff, L.M., Skeate, J.G., Yan, L., Da Silva, D.M., etal. (2013) The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol. doi:10.1128/JVI.00330-13
63. Richards, R.M., Lowy, D.R., Schiller, J.T., and Day, P.M. (2006) Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci USA 103: 1522-1527.
64. Rigler, R., and Elson, E. (2001) Fluorescence Correlation Spectroscopy: Theory and Applications. Berlin: Springer Verlag.
65. Rommel, O., Dillner, J., Fligge, C., Bergsdorf, C., Wang, X., Selinka, H.C., and Sapp, M. (2005) Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA. J Med Virol 75: 114-121.
66. Saitoh, H., and Hinchey, J. (2000) Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 275: 6252-6258.
67. Sapp, M., and Day, P.M. (2009) Structure, attachment and entry of polyoma- and papillomaviruses. Virology 384: 400-409.
68. Sapp, M., Kraus, U., Volpers, C., Snijders, P.J., Walboomers, J.M., and Streeck, R.E. (1994) Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein. J Gen Virol 75: 3375-3383.
69. Sapp, M.J. (2013) HPV virions hitchhike a ride on retromer complexes. Proc Natl Acad Sci USA 110: 7116-7117.
70. Scheffer, K.D., Gawlitza, A., Spoden, G.A., Zhang, X.A., Lambert, C., Berditchevski, F., and Florin, L. (2013) Tetraspanin CD151 mediates papillomavirus type 16 endocytosis. J Virol 87: 3435-3446.
71. Schelhaas, M., Shah, B., Holzer, M., Blattmann, P., Kuhling, L., Day, P.M., etal. (2012) Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog 8: e1002657.
72. Schneider, M.A., Spoden, G.A., Florin, L., and Lambert, C. (2011) Identification of the dynein light chains required for human papillomavirus infection. Cell Microbiol 13: 32-47.
73. Schwartz, S. (2008) HPV-16 RNA processing. Front Biosci 13: 5880-5891.
74. Seeler, J.-S., and Dejean, A. (2003) Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol 4: 690-699.
75. Sekiyama, N., Ikegami, T., Yamane, T., Ikeguchi, M., Uchimura, Y., Baba, D., etal. (2008) Structure of the small ubiquitin-like modifier (SUMO)-interacting motif of MBD1-containing chromatin-associated factor 1 bound to SUMO-3. J Biol Chem 283: 35966-35975.
76. Selinka, H.-C., Florin, L., Patel, H.D., Freitag, K., Schmidtke, M., Makarov, V.A., and Sapp, M. (2007) Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol 81: 10970-10980.
77. Shafti-Keramat, S., Handisurya, A., Kriehuber, E., Meneguzzi, G., Slupetzky, K., and Kirnbauer, R. (2003) Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 77: 13125-13135.
78. Song, J., Durrin, L.K., Wilkinson, T.A., Krontiris, T.G., and Chen, Y. (2004) Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci USA 101: 4373-14378.
79. Song, J., Zhang, Z., Hu, W., and Chen, Y. (2005) Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif: a reversal of the bound orientation. J Biol Chem 280: 40122-40129.
80. Spoden, G., Freitag, K., Husmann, M., Boller, K., Sapp, M., Lambert, C., and Florin, L. (2008) Clathrin- and caveolin-independent entry of human papillomavirus type 16 - involvement of tetraspanin-enriched microdomains (TEMs). PLoS ONE 3: e3313.
81. Spoden, G., Kuhling, L., Cordes, N., Frenzel, B., Sapp, M., Boller, K., etal. (2013) The Human Papillomaviruses Type 16, 18, and 31 share similar endocytic requirements for entry. J Virol 87: 7765-7773.
82. Spoden, G.A., Besold, K., Krauter, S., Plachter, B., Hanik, N., Kilbinger, A.F.M., etal. (2011) Polyethylenimine is a strong inhibitor of human papillomavirus and cytomegalovirus infection. Antimicrob Agents Chemother 56: 75-82.
83. Stehmeier, P., and Muller, S. (2009) Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol Cell 33: 400-409.
84. Stepp, W.H., Meyers, J.M., and McBride, A.A. (2013) Sp100 provides intrinsic immunity against human papillomavirus infection. MBio 4: 845-857.
85. Stoll, S., and Schweiger, A. (2006) EasySpin, a comprehensive software package for spectral simulation and analysis in EPR. J Magn Reson 178: 42-55.
86. Surviladze, Z., Dziduszko, A., and Ozbun, M.A. (2012) Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog 8: e1002519.
87. Tatham, M.H., Geoffroy, M.C., Shen, L., Plechanovova, A., Hattersley, N., Jaffray, E.G., etal. (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10: 538-546.
88. Tavalai, N., and Stamminger, T. (2008) New insights into the role of the subnuclear structure ND10 for viral infection. Biochim Biophys Acta 1783: 2207-2221.
89. Tavalai, N., and Stamminger, T. (2009) Interplay between herpesvirus infection and host defense by PML nuclear bodies. Viruses 1: 1240-1264.
90. Van Damme, E., and Van Ostade, X. (2011) Crosstalk between viruses and PML nuclear bodies: a network-based approach. Front Biosci 17: 2910-2920.
91. Vertegaal, A.C. (2010) SUMO chains: polymeric signals. Biochem Soc Trans 38: 46-49.
92. Volpers, C., Sapp, M., Snijders, P.J., Walboomers, J.M., and Streeck, R.E. (1995) Conformational and linear epitopes on virus-like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2. J Gen Virol 76: 2661-2667.
93. Wadosky, K.M., and Willis, M.S. (2011) The story so far: post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation. Am J Physiol Heart Circ Physiol 302: H515-H526.
94. Wang, L., Oliver, S.L., Sommer, M., Rajamani, J., Reichelt, M., and Arvin, A.M. (2011) Disruption of PML nuclear bodies is mediated by ORF61 SUMO-interacting motifs and required for varicella-zoster virus pathogenesis in skin. PLoS Pathog 7: e1002157.
95. Waterhouse, A.M., Procter, J.B., Martin, D.M., Clamp, M., and Barton, G.J. (2009) Jalview Version 2 - a multiple sequence alignment editor and analysis workbench. Bioinformatics 25: 1189-1191.
96. Wimmer, P., Schreiner, S., and Dobner, T. (2012) Human pathogens and the host cell SUMOylation system. J Virol 7: 211-225.
97. Woodham, A.W., Da Silva, D.M., Skeate, J.G., Raff, A.B., Ambroso, M.R., Brand, H.E., etal. (2012) The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS ONE 7: e43519.
98. Yang, S.H., and Sharrocks, A.D. (2010) The SUMO E3 ligase activity of Pc2 is coordinated through a SUMO interaction motif. Mol Cell Biol 30: 2193-2205.